Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond 9 to 12 months of ADT. HealthDay News — Increasing duration of androgen deprivation therapy (ADT) ...

Androgen-deprivation therapy (ADT) has become the mainstay of treatment for metastatic prostate cancer. ADT's testosterone depletion, however, leads to side effects that impair health-related ...

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer. The combination of Nubeqa (darolutamide) ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...